已收盤 02-06 16:00:00 美东时间
+0.110
+0.61%
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - February ...
02-07 04:00
今日重点评级关注:富国银行:维持Milestone Pharmaceuticals"超配"评级,目标价从4美元升至8美元;富国银行:维持Kyverna Therapeutics"超配"评级,目标价从31美元升至33美元
2025-12-17 10:46
Small Cap Consumer Research analyst Eric M Beder reiterates Jakks Pacific (NASDAQ:JAKK) with a Buy and maintains $30 price target.
2025-12-16 23:35
JAKKS Pacific, Inc. (NASDAQ: JAKK), a leading designer and marketer of toys, and The Hershey Company, one of the world's largest confectionery brands, announced today a new partnership that will bring the beloved HersheyJAKKS Pacific, Inc.
2025-12-04 22:02
JAKKS Pacific和The Hershey Company宣布达成新合作,将Hershey品牌融入Charming系列小玩偶和收藏品,推出首款糖果主题产品线。该系列包括8款SKU,灵感源自Hershey’s Kisses、Jolly Rancher、Reese’s等 popular treats,每款产品都配有独特主题饰品和配件。Hershey’s Kisses系列将于2025年12月26日在CVS独家上市,旨在情人节前吸引消费者。该合作将持续至2026年12月31日,未来有望延长。Charming Bag Charms系列作为随身玩具,可挂在包、背包或手机上,支持孩子随时更换造型,极具趣味性和互动性。
2025-12-04 14:00
Disguise Inc. has been ranked the #1 costume manufacturer in the U.S. for year-to-date 2025, marking its third consecutive year in the top spot. Minecraft, its top license, driven by the success of *A Minecraft Movie*, significantly contributed to this achievement. The Chicken Jockey Pop-Up Costume, inspired by the film, became a huge hit, with its demand boosted by a viral fan trend. Disguise's success is attributed to its commitment to quality ...
2025-11-18 13:00
The U.S. corporate sector is experiencing a significant surge in earnings, with the growth rate hitting a four-year high despite concerns over the impact of the trade war initiated by President Donald Trump.
2025-11-10 20:18
JAKKS Pacific (JAKK) declares $0.25/share quarterly dividend. Forward yield 5.97% Payable Dec. 29; for shareholders of record Nov. 28; ex-div Oct. 28. See JAKK Dividend Scorecard, Yield Chart, & Divid...
2025-10-31 22:53
JAKKS Pacific shares are trading lower after the company reported worse-than-ex...
2025-10-31 05:10
今日重点评级关注:摩根士丹利:维持Viking Therapeutics"超配"评级,目标价从98美元升至102美元;摩根大通:维持IDEAYA Biosciences"超配"评级,目标价从74美元升至79美元
2025-10-24 09:51